Veracyte’s $137.9 Million Public Offering

Fenwick & West represented Veracyte, Inc. in the transaction.

Veracyte, Inc. (Nasdaq: VCYT), a pioneering genomic diagnostics company, closed a public offering of 6,325,000 shares of its common stock, including 825,000 shares upon full exercise of the underwriters’ option, at an offering price of $23.25 per share.

The net proceeds to Veracyte were approximately $137.9 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Morgan Stanley and SVB Leerink are acting as lead book-running managers for the offering. William Blair is acting as a book-running manager and BTIG and Janney Montgomery Scott are acting as co-managers.

The Fenwick transaction team included corporate lawyers Doug Cogen (Picture), Rob Freedman, Ran Ben-Tzur, Michael Shaw, Veronica Zavala and Vincent Sheu.

Involved fees earner: Ran Ben-Tzur – Fenwick & West LLP; Douglas Cogen – Fenwick & West LLP; Robert Freedman – Fenwick & West LLP; Michael Shaw – Fenwick & West LLP; Vincent Sheu – Fenwick & West LLP; Veronica Zavala – Fenwick & West LLP;

Law Firms: Fenwick & West LLP;

Clients: Veracyte, Inc.;

Author: Ambrogio Visconti